Joyce V. Thompson

Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Maintenance Capecitabine Plus Ramucirumab After First-Line Chemotherapy in Patients With Advanced Esophagogastric Adenocarcinoma: Results From the Randomized PLATFORM Study.

Maintenance Capecitabine Plus Ramucirumab After First-Line Chemotherapy in Patients With Advanced Esophagogastric Adenocarcinoma: Results From the Randomized PLATFORM Study.

Journal: JCO oncology advances

Published: September 18, 2024

External validation of the Oldham composite Covid-19 associated mortality model (OCCAM), a prognostic model for death in patients hospitalised with Covid-19.

External validation of the Oldham composite Covid-19 associated mortality model (OCCAM), a prognostic model for death in patients hospitalised with Covid-19.

Journal: Infectious diseases now

Published: August 30, 2022

Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).

Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).

Journal: Circulation

Published: July 25, 2022

Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH).

Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH).

Journal: BMC cancer

Published: March 25, 2021

Patient characteristics and predictors of mortality in 470 adults admitted to a district general hospital in England with Covid-19.

Patient characteristics and predictors of mortality in 470 adults admitted to a district general hospital in England with Covid-19.

Journal: Epidemiology and infection

Published: November 24, 2020

Utility of COVID-19 Screening in Cancer Patients.

Utility of COVID-19 Screening in Cancer Patients.

Journal: Cancer cell

Published: July 31, 2020

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial.

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial.

Journal: JAMA oncology

Published: June 21, 2019

Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.

Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 25, 2017

Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.

Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 10, 2017

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.

Journal: The Lancet. Oncology

Published: April 26, 2017

Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 23, 2017

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 28, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026